SubsidieMeestersThe first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance
Tafalgie Therapeutics aims to develop non-opioid analgesics using innovative polypeptides from TAFA4 to provide effective, non-addictive pain relief and prevent chronic pain.
Projectdetails
Introduction
Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal.
Ambition
Our ambition is to become the reference player in the field of pain medication by:
- Designing and proposing new active pharmaceutical ingredients for non-opioid analgesics.
- Addressing the context marked by the opioid crisis.
- Developing first-in-class polypeptides derived from TAFA4 and its peptide derivatives.
Goals
We aim to develop and bring to patients:
- More effective treatments for the relief of acute pain - mild, moderate, and severe.
- Well-tolerated, non-addictive, long-term treatments.
- Solutions for the prevention of chronic pain.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 17.388.832 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- TAFALGIE THERAPEUTICSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC COG | € 1.998.885 | 2023 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC POC | € 150.000 | 2023 | Details |
Oral oxytocin for abdominal painThis project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens. | ERC POC | € 150.000 | 2023 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Oral oxytocin for abdominal pain
This project aims to develop gut-stable peptide analgesics for effective oral treatment of chronic abdominal pain, addressing a significant unmet medical need and reducing socio-economic burdens.